Skip to main content
Fig. 3 | Lipids in Health and Disease

Fig. 3

From: International practice patterns of dyslipidemia management in patients with chronic kidney disease under nephrology care: is it time to review guideline recommendations?

Fig. 3

Distribution of LDL-C (mg/dL) by country and statin use and intensity. Statin use was ascertained within 6 months before the LDL-C measurement. To determine statin intensity, patients with no statin use in that time window were categorized as “none”; patients using atorvastatin or rosuvastatin ever within the window were categorized as “high”; and patients using any other statin were categorized as “low”

Back to article page

Lipids in Health and Disease

ISSN: 1476-511X